Duke Eye Center

Welcome to Duke Eye Center, Class of 2030! We’re excited to have these new ophthalmology residents join our team and look forward to supporting their training, growth, and success in the years ahead.

We’re proud to share another story from our 2026 VISION magazine - a landmark moment in retinal care.

Duke became the first U.S. academic medical center to implant Encelto, a newly FDA‑approved cell‑based therapy for macular telangiectasia type 2. Led by Lejla Vajzovic, MD, FASRS, the procedure offers new hope for patients facing progressive central vision loss.

This milestone reflects years of Duke‑driven research, including the discovery of ellipsoid zone loss as an FDA‑recognized endpoint by Glenn Jaffe, MD, Eleonora (Nora) Lad, MD, PhD, and Sina Farsiu, PhD. Their work, along with advances in AI‑powered retinal analysis, helped bring the first MacTel treatment from concept to clinic.

Read: https://heyzine.com/flip-book/0fa2e7615b.html /21

Sharing highlights from the 2026 Duke Eye Center Trainee Graduation Banquet! It’s always an honor to celebrate our residents and fellows and recognize their achievements across research, education, innovation, and clinical care.

Congratulations to all award recipients and to the entire Class of 2026 as they take their next steps in ophthalmology.

https://dukeeyecenter.duke.edu/news/celebrating-duke-ophthalmology-class-2026

Proud to share this powerful story from Duke Health CEO Dr. David Zaas about how surviving leukemia shaped his approach to patient‑centered leadership.

How surviving leukemia changed Duke Health CEO's approach to patient care A life-threatening leukemia diagnosis forced Dr. David Zaas to experience healthcare from the other side of the hospital bed. Now, the new Duke University Health System CEO says those lessons are guiding his approach to patient care and the future of Duke Health.